Business Context and Reporting Period
Company: Recursion Pharmaceuticals, Inc. (RXRX)
Filing Type: Form 8-K (Current Report)
Date of Report: December 8, 2025
Event: Announcement of Phase 1b/2 clinical trial data for the investigational drug REC-4881.
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding a clinical trial update and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The material event reported is the release of Phase 1b/2 data from the ongoing TUPELO trial for REC-4881, an investigational allosteric MEK1/2 inhibitor designed to treat familial adenomatous polyposis (FAP). No financial material changes are reported in this document.
Guidance, Outlook, and Risks
- Management Commentary: The Company issued a press release and a data presentation regarding the TUPELO trial results on December 8, 2025.
- Exhibits: The press release (Exhibit 99.1) and the data presentation (Exhibit 99.2) are incorporated by reference.
- Risks and Contingencies: This specific filing does not detail new risks or contingencies beyond the inherent uncertainties of clinical trial outcomes referenced in the attached exhibits.
Investor Verification Checklist
- Review the attached Press Release (Exhibit 99.1) for specific efficacy and safety data from the TUPELO trial.
- Analyze the Data Presentation (Exhibit 99.2) for detailed statistical results regarding REC-4881.
- Verify the regulatory implications of the Phase 1b/2 data for the treatment of familial adenomatous polyposis (FAP).
- Check subsequent filings for any impact of these results on the Company's cash burn rate or future capital requirements.